Company research / RVPH
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Key ratios (year ended 2025-12-31)
-229.7%
Return on year-end equity
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $6.70M | $11.71M | $22.91M | $31.42M | n/a | n/a | n/a | $22.87M | n/a | $4.85M | $295.1K |
| Operating Income | -$13.48M | -$20.20M | -$30.80M | -$39.50M | n/a | n/a | n/a | -$28.23M | n/a | -$10.10M | -$2.43M |
| Net Income | -$13.02M | -$19.86M | -$29.92M | -$39.26M | n/a | n/a | n/a | -$28.26M | n/a | -$8.52M | -$3.78M |
| Total Assets | $21.14M | $15.92M | $15.50M | $23.70M | n/a | n/a | n/a | $18.92M | n/a | $31.40M | $8.76M |
| Total Liabilities | $5.93M | $7.28M | $14.69M | $17.98M | $18.20M | $13.66M | $11.29M | $10.53M | $6.49M | $2.72M | $3.30M |
| Shareholders' Equity | $15.21M | $8.65M | $812.6K | $5.72M | -$12.81M | -$1.82M | $1.61M | $8.39M | $17.56M | $28.69M | $5.47M |
| Cash & Equivalents | $19.89M | $14.44M | $13.48M | $23.37M | n/a | n/a | n/a | $18.52M | n/a | $29.69M | $8.76M |
| Operating Cash Flow | -$17.30M | -$24.59M | -$33.54M | -$28.32M | n/a | n/a | n/a | -$18.96M | n/a | -$10.67M | -$4.07M |
| Shares Outstanding | 13.11M | 5.87M | 2.36M | 27.92M | n/a | n/a | n/a | 20.45M | n/a | 14.43M | 9.23M |
| EPS (Basic) | n/a | -$5.48 | -$17.73 | -$1.65 | n/a | n/a | n/a | -$1.45 | n/a | -$0.58 | n/a |